Welcome to our dedicated page for CYAD news (Ticker: CYAD), a resource for investors and traders seeking the latest updates and insights on CYAD stock.
CYAD (Celyad Oncology SA) provides a centralized hub for tracking developments in clinical-stage cell therapies and immuno-oncology innovations. This resource aggregates essential updates including trial progress, regulatory milestones, and strategic partnerships critical for evaluating the company's position in cancer treatment research.
Investors and researchers will find curated press releases detailing CYAD's NKR-T cell programs, manufacturing advancements, and collaborative initiatives with institutions like Dartmouth College. The collection emphasizes factual reporting on phase transitions, financial disclosures, and operational updates without speculative commentary.
Content spans clinical trial authorizations, intellectual property developments, and executive leadership changes. Regular updates ensure stakeholders maintain current awareness of CYAD's progress in translating cell-based therapies from laboratory research to clinical applications.
Bookmark this page for streamlined access to verified CYAD developments. Combine periodic reviews with real-time monitoring for comprehensive analysis of the company's evolving role in advanced cancer treatment solutions.
Celyad Oncology (NASDAQ:CYAD) has announced a collaboration with MSD to conduct the Phase 1b KEYNOTE-B79 clinical trial. This trial will investigate the investigational allogeneic CAR T candidate, CYAD-101, in combination with MSD's KEYTRUDA® for treating refractory metastatic colorectal cancer patients. The collaboration aims to leverage the complementary mechanisms of both therapies, potentially addressing unmet needs in microsatellite stable disease. Encouraging results from the alloSHRINK trial provide a positive backdrop for this initiative.
Celyad Oncology, a clinical-stage biotechnology company, announced that CEO Filippo Petti will participate in a fireside chat at the Jefferies Cell Therapy Summit on October 5, 2020, at 11:00 a.m. EDT. The event will be available for investors to listen to via a live webcast on the company's website, with an archived replay accessible for 30 days. Celyad focuses on developing CAR T cell therapies for cancer, including allogeneic and autologous candidates for treating hematological malignancies and solid tumors. The company, founded in 2007, is based in Belgium and New York.
Celyad Oncology (CYAD), a clinical-stage biotechnology company, will host a Research & Development webinar on September 29 at 11:00 a.m. EDT. The webinar will provide insights on its CAR T candidates, CYAD-101 for metastatic colorectal cancer and CYAD-211 for relapsed/refractory multiple myeloma. Dr. Richard Kim will discuss immuno-oncology treatments. Celyad's management will share updates on its pipeline and future directions. Interested participants can register for the live webcast through the company's website, where a replay will also be available post-event.
Celyad Oncology has announced an Open Market Sale Agreement with Jefferies LLC to sell up to $25 million of new American Depositary Shares (ADSs) through an at-the-market offering. The ADSs are priced at $9.91 each, representing a potential issuance of up to 2,777,777 shares. Proceeds from this offering will primarily support the company's CAR T cell therapy research and development initiatives. The offering is registered under a shelf registration statement effective as of September 4, 2020, with additional details available from Jefferies.
Celyad Oncology SA (CYAD) announced its participation in several conferences in September 2020, including the Wells Fargo 2020 Virtual Healthcare Conference and the H.C. Wainwright 22nd Annual Global Investment Conference. The company, based in Mont-Saint-Guibert, Belgium, focuses on developing CAR T cell therapies for cancer. Celyad is advancing both allogeneic and autologous therapy candidates for hematological malignancies and solid tumors. The press release includes a forward-looking statement about the expected initiation of a Phase 1 trial by year-end 2020.
Celyad Oncology announced that the FDA has granted permission for the Phase 1 clinical trial of CYAD-211, its first shRNA-based allogeneic CAR T candidate targeting BCMA for relapsed/refractory multiple myeloma. The trial is set to begin by the end of 2020. CYAD-211 is part of the CYAD-200 series and utilizes a unique shRNA technology platform. This marks a significant advancement for Celyad, demonstrating its ability to effectively develop multiple off-the-shelf CAR T therapies.
Celyad SA (Euronext & Nasdaq: CYAD) announced a corporate rebranding to Celyad Oncology, reflecting its commitment to pioneering CAR T cell therapies for cancer. This change accompanies the launch of a new logo and website, aimed at emphasizing the company’s progress in next-generation CAR T programs. CEO Filippo Petti highlighted the firm’s expertise and strategic focus on innovative cell therapies, particularly in the context of recent developments discussed at the American Society of Clinical Oncology conference.
Celyad (CYAD), a clinical-stage biopharmaceutical company, announced its participation in several virtual investor conferences in June 2020. The conferences include: Jefferies Virtual Healthcare Conference from June 2-4, William Blair 40th Annual Growth Stock Conference on June 10 at 2:00 p.m. CDT, and Kepler Cheuvreux Digital Belgian Life Science Day on June 22 at 3:10 p.m. CEST. Celyad is advancing CAR-T cell therapies targeting various cancers, with significant clinical trials ongoing for lead candidates CYAD-01 and CYAD-101.
Celyad (NASDAQ: CYAD) reported operational updates for Q1 2020, highlighting the progression of CAR-T therapies despite COVID-19 challenges. The company initiated the Phase 1 CYCLE-1 trial for CYAD-02 targeting relapsed/refractory AML and MDS. With a treasury of €33.8 million, Celyad expects sufficient funds to support operations through mid-2021. Key milestones include data announcements for CYAD-101 at the ASCO Virtual Scientific Program and the IND application filing for CYAD-211. Preliminary data from trials show promising early signs of clinical activity.
Celyad, a clinical-stage biopharmaceutical company focused on CAR-T therapies, announced the appointments of Dr. Maria Koehler and Mr. Dominic Piscitelli to its Board of Directors, effective March 24 and May 6, 2020. Dr. Koehler, with over 20 years in oncology drug development, and Mr. Piscitelli, who has extensive experience in financial operations, will enhance Celyad's strategic and operational capabilities. The company is advancing its CAR-T therapies, including CYAD-01, in various clinical trials to treat hematological malignancies and solid tumors.
FAQ
What is the market cap of CYAD (CYAD)?
